Cara Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-07-02
- Employees
- 55
- Market Cap
- $19.6M
- Introduction
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
- Conditions
- PruritusUremic Pruritus
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT02229929
- Locations
- 🇺🇸
University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States
🇺🇸North American Research Institute, San Dimas, California, United States
🇺🇸Valley Renal Medical Group, Northridge, California, United States
A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01789476
- Locations
- 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT01361568
- Locations
- 🇺🇸
Visions Clinical Research, Boynton Beach, Florida, United States
🇺🇸Woodland Healthcare California Clinical Research, Inc, Davis, California, United States
🇺🇸Texas Health Care, PLLC, Fort Worth, Texas, United States
Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT00877799
- Locations
- 🇺🇸
Springhill Medical Center, Mobile, Alabama, United States
🇺🇸The Woman's Hospital of Texas, Houston, Texas, United States
🇺🇸Paradise Valley Hospital, Phoenix, Arizona, United States